Caplacizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Caplacizumab
Accession Number
DB06081
Type
Small Molecule
Groups
Investigational
Description

ALX-0081 is a novel ‘first-in-class’ therapeutic Nanobody® targeting von Willebrand Factor (vWF), which can reduce the risk of thrombosis in patients with acute coronary syndrome. ALX-0081 is intended to prevent arterial thrombosis, without interfering with the desired haemostatis (wound healing) in the patient which results in less bleeding complications.

Synonyms
Not Available
External IDs
ALX-0081
Categories
UNII
2R27AB6766
CAS number
915810-67-2
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in cardiovascular disorders and thrombosis.

Structured Indications
Not Available
Pharmacodynamics

ALX-0081 is intended to prevent arterial thrombosis, without interfering with the desired haemostatis (wound healing) in the patient which results in less bleeding complications.

Mechanism of action

ALX-0081 is a Nanobody® targeted against von Willebrand Factor (vWF), a protein found in the blood, that acts at a very early stage in the coagulation cascade, namely platelet adhesion, in contrast to currently available anti-platelet drugs which work only in the late stage of platelet aggregation. The addition of ALX-0081 to the range of tools currently employed in an anti-thrombotic regimen may, therefore, have the potential to improve the overall efficacy of anti-platelet aggregation therapy and lead to an increased use of anti-thrombotic treatment in clinical indications like ACS where there is a high need for immediate and safe therapy.

TargetActionsOrganism
Uvon Willebrand factorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabCaplacizumab may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolCaplacizumab may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Caplacizumab.Approved, Vet Approved
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Caplacizumab.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Caplacizumab.Approved, Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Caplacizumab.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Caplacizumab.Approved
AncrodCaplacizumab may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Caplacizumab.Investigational
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Caplacizumab.Approved
Antithrombin III humanCaplacizumab may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanCaplacizumab may increase the anticoagulant activities of Apixaban.Approved
AprotininThe therapeutic efficacy of Caplacizumab can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinCaplacizumab may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanCaplacizumab may increase the anticoagulant activities of Argatroban.Approved, Investigational
AzelastineAzelastine may increase the anticoagulant activities of Caplacizumab.Approved
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Caplacizumab.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Caplacizumab.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Caplacizumab.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Caplacizumab.Investigational
BecaplerminCaplacizumab may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeraprostBeraprost may increase the anticoagulant activities of Caplacizumab.Investigational
BivalirudinCaplacizumab may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BuflomedilBuflomedil may increase the anticoagulant activities of Caplacizumab.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Caplacizumab.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Caplacizumab.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Caplacizumab.Experimental, Investigational
CertoparinCaplacizumab may increase the anticoagulant activities of Certoparin.Approved, Investigational
CilostazolCilostazol may increase the anticoagulant activities of Caplacizumab.Approved, Investigational
Citric AcidCaplacizumab may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Caplacizumab.Approved
CloricromenCloricromen may increase the anticoagulant activities of Caplacizumab.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Caplacizumab.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Caplacizumab.Approved
Dabigatran etexilateCaplacizumab may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinCaplacizumab may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidCaplacizumab may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanCaplacizumab may increase the anticoagulant activities of Darexaban.Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Caplacizumab.Approved, Investigational
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Caplacizumab.Investigational
DesirudinCaplacizumab may increase the anticoagulant activities of Desirudin.Approved
DextranCaplacizumab may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Caplacizumab may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Caplacizumab may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Caplacizumab may increase the anticoagulant activities of Dextran 75.Approved
DicoumarolCaplacizumab may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Caplacizumab.Approved, Investigational
DipyridamoleDipyridamole may increase the anticoagulant activities of Caplacizumab.Approved
Edetic AcidCaplacizumab may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanCaplacizumab may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinCaplacizumab may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Caplacizumab.Approved, Investigational
EplivanserinEplivanserin may increase the anticoagulant activities of Caplacizumab.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Caplacizumab.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Caplacizumab.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Caplacizumab.Approved, Investigational
Ethyl biscoumacetateCaplacizumab may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidCaplacizumab may increase the anticoagulant activities of Ferulic acid.Experimental
FluindioneCaplacizumab may increase the anticoagulant activities of Fluindione.Approved, Investigational
FondaparinuxCaplacizumab may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumCaplacizumab may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Caplacizumab.Investigational
GabexateCaplacizumab may increase the anticoagulant activities of Gabexate.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Caplacizumab.Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Caplacizumab.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Caplacizumab.Experimental
HeparinCaplacizumab may increase the anticoagulant activities of Heparin.Approved, Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Caplacizumab.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Caplacizumab.Approved, Withdrawn
Human rabies virus immune globulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Caplacizumab.Approved
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Caplacizumab.Investigational
IbudilastIbudilast may increase the anticoagulant activities of Caplacizumab.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Caplacizumab.Approved, Investigational, Nutraceutical
IdraparinuxCaplacizumab may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Caplacizumab.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Caplacizumab.Investigational
IloprostIloprost may increase the anticoagulant activities of Caplacizumab.Approved, Investigational
IndobufenIndobufen may increase the anticoagulant activities of Caplacizumab.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Caplacizumab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Caplacizumab.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Caplacizumab.Approved
KetanserinKetanserin may increase the anticoagulant activities of Caplacizumab.Investigational
LepirudinCaplacizumab may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanCaplacizumab may increase the anticoagulant activities of Letaxaban.Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Caplacizumab.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Caplacizumab.Experimental
MelagatranCaplacizumab may increase the anticoagulant activities of Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Caplacizumab.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Caplacizumab.Approved, Vet Approved
MilrinoneMilrinone may increase the anticoagulant activities of Caplacizumab.Approved
NadroparinCaplacizumab may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatCaplacizumab may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilNaftopidil may increase the anticoagulant activities of Caplacizumab.Investigational
NimesulideNimesulide may increase the anticoagulant activities of Caplacizumab.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Caplacizumab.Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Caplacizumab.Approved
OtamixabanCaplacizumab may increase the anticoagulant activities of Otamixaban.Investigational
Pentaerythritol TetranitrateCaplacizumab may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateCaplacizumab may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Caplacizumab.Approved, Investigational
PhenindioneCaplacizumab may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonCaplacizumab may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PicotamidePicotamide may increase the anticoagulant activities of Caplacizumab.Experimental
PrasugrelPrasugrel may increase the anticoagulant activities of Caplacizumab.Approved
Protein CCaplacizumab may increase the anticoagulant activities of Protein C.Approved
Protein S humanCaplacizumab may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeCaplacizumab may increase the anticoagulant activities of Protocatechualdehyde.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Caplacizumab.Approved, Investigational
RamatrobanRamatroban may increase the anticoagulant activities of Caplacizumab.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Caplacizumab.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Caplacizumab.Approved, Experimental, Investigational
ReviparinCaplacizumab may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Caplacizumab.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Caplacizumab.Investigational
RivaroxabanCaplacizumab may increase the anticoagulant activities of Rivaroxaban.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Caplacizumab.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Caplacizumab.Approved, Investigational
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Caplacizumab.Approved, Investigational, Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Caplacizumab.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Caplacizumab.Approved
SarpogrelateSarpogrelate may increase the anticoagulant activities of Caplacizumab.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Caplacizumab.Approved, Vet Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Caplacizumab.Investigational
SRT501SRT501 may increase the anticoagulant activities of Caplacizumab.Investigational
SulodexideCaplacizumab may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Caplacizumab.Investigational
TesmilifeneTesmilifene may increase the anticoagulant activities of Caplacizumab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Caplacizumab.Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Caplacizumab.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Caplacizumab.Approved
TirofibanTirofiban may increase the anticoagulant activities of Caplacizumab.Approved
TranilastTranilast may increase the anticoagulant activities of Caplacizumab.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Caplacizumab.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Caplacizumab is combined with Treprostinil.Approved, Investigational
TriflusalTriflusal may increase the anticoagulant activities of Caplacizumab.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Caplacizumab.Approved
TroxerutinCaplacizumab may increase the anticoagulant activities of Troxerutin.Investigational
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Caplacizumab.Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Caplacizumab.Approved
WarfarinCaplacizumab may increase the anticoagulant activities of Warfarin.Approved
XimelagatranCaplacizumab may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Caplacizumab.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Caplacizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentNon ST Segment Elevation Myocardial Infarction (NSTEMI) / Stable Angina (Associated With High Risk PCI) / Unstable Angina (UA)1
3Active Not RecruitingTreatmentAcquired Thrombotic Thrombocytopenic Purpura1
3CompletedTreatmentAcquired Thrombotic Thrombocytopenic Purpura1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein n-terminus binding
Specific Function
Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surf...
Gene Name
VWF
Uniprot ID
P04275
Uniprot Name
von Willebrand factor
Molecular Weight
309261.83 Da

Drug created on November 18, 2007 11:29 / Updated on February 03, 2018 13:58